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Abstract
Background: Poor control of type 2 diabetes results in substantial long-term consequences.
Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and
costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both
added to glimepiride.
Methods:  To estimate long-term clinical and economic consequences, we used the CORE
diabetes model, a validated cohort model that uses epidemiologic data from long-term clinical trials
to simulate morbidity, mortality and costs of diabetes. Clinical data were extracted from the LEAD-
1 trial evaluating two doses (1.2 mg and 1.8 mg) of a once daily GLP-1 analog liraglutide, or
rosiglitazone 4 mg, on a background of glimepiride in type 2 diabetes. CORE was calibrated to the
LEAD-1 baseline patient characteristics. Survival, cumulative incidence of cardiovascular, ocular and
renal events and healthcare costs were estimated over three periods: 10, 20 and 30 years.
Results: In a hypothetical cohort of 5000 patients per treatment followed for 30 years, liraglutide
1.2 mg and 1.8 mg had higher survival rates compared to the group treated with rosiglitazone
(15.0% and 16.0% vs. 12.6% after 30 years), and fewer cardiovascular, renal, and ocular events.
Cardiovascular death rates after 30 years were 69.7%, 68.4% and 72.5%, for liraglutide 1.2 mg, 1.8
mg, and rosiglitazone, respectively. First and recurrent amputations were lower in the rosiglitazone
group, probably due to a 'survival paradox' in the liraglutide arms (number of events: 565, 529, and
507, respectively). Overall cumulative costs per patient, were lower in both liraglutide groups
compared to rosiglitazone (US$38,963, $39,239, and $40,401 for liraglutide 1.2 mg, 1.8 mg, and
rosiglitazone, respectively), mainly driven by the costs of cardiovascular events in all groups.
Conclusion: Using data from LEAD-1 and epidemiologic evidence from the CORE diabetes
model, projected rates of mortality, diabetes complications and healthcare costs over the long term
favor liraglutide plus glimepiride over rosiglitazone plus glimepiride.
Trial registration: LEAD-1 NCT00318422; LEAD-2 NCT00318461; LEAD-3 NCT 00294723;
LEAD-4 NCT00333151; LEAD-5 NCT00331851; LEAD-6 NCT00518882.
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Background
Type 2 diabetes is a chronic disease associated with insu-
lin resistance and a progressive failure of the pancreatic
beta cells. [1-3]. Type 2 diabetes is believed to account for
about 90% of all cases of diabetes [4]. The American Dia-
betes Association (ADA) reported that, in the USA in
2007, 17.5 million people were diagnosed with diabetes.
Estimates from the Centers for Disease Control and Pre-
vention (CDC), which include persons with both diag-
nosed and undiagnosed diabetes, place the number of
Americans with diabetes at 23.6 million [5]. The number
of people with diagnosed diabetes is growing at a rate of 1
million per year [6], and is projected to reach over 48 mil-
lion by 2050 [7]. The impact of diabetes on the US econ-
omy is alarming, with a total estimated cost of US$174
billion in 2007. A majority of the economic burden, $116
billion, can be attributed to expenditures for medical care
[6]. A majority of these costs are for treatment of compli-
cations of the disease [8-11].
Large population-based studies have established that dia-
betes is associated with increased rates of cardiovascular
morbidity and death [12-15]. Clinical trials have shown
the benefits of intensive glucose lowering therapies to
reduce the risk of microvascular disease [1], cardiovascu-
lar events and death [16,17], or the combined risk of
micro- and macrovascular events [18], in diabetic
patients. Diabetes-related complications greatly diminish
patients' health-related quality of life [19-21]. More
recently, new evidence suggest that intensive treatment
and extreme reductions in HbA1c below 6.5%, may have
no effect, or (in one study) even increase the rate of cardi-
ovascular events and death in high risk patients with dia-
betes [18,22]. Thus, until this new evidence can be
completely understood and supported by large longitudi-
nal studies, it seem plausible that an intervention target-
ing reduction in glycemia levels to current guidelines, as
well as improving concomitant risk factors, such as blood
pressure, lipid levels and bodyweight might prevent and
reduce the risk of micro- and macro-vascular complica-
tions. This intervention has recently been endorsed by a
position statement of the American Diabetes Association
and a scientific statement of the American College of Car-
diology Foundation and the American Heart Association
[23].
Liraglutide is a new once-daily human glucagon-like pep-
tide (GLP)-1 analog. GLP-1 is a natural glucose-regulating
peptide that enhances insulin secretion and reduces gluca-
gon secretion, both in a glucose-dependent manner. Nat-
urally occurring GLP-1 would require continuous
infusion because of its short half-life, and so is impractical
for routine therapeutic use; therefore, GLP-1 receptor ago-
nists with an extended duration of action have been devel-
oped. The efficacy and safety of liraglutide treatment has
been investigated both as monotherapy [24], and in com-
bination with a number of currently approved therapies
(metformin, sulfonylurea, thiazolidinediones) for type 2
diabetes in a large phase 3a trial program with extensive
use of active comparators (the Liraglutide Effect and
Action in Diabetes [LEAD 1–6] trial program) [25-30].
Our objective was to model the long-term outcomes of
adding either liraglutide or rosiglitazone to glimepiride in
patients with type 2 diabetes using data from the LEAD-1
clinical trial and a validated simulation model (CORE) of
type 2 diabetes.
Methods
Background
Data on subject characteristics at baseline and treatment
effects were extracted from the LEAD-1 study, which com-
pared the efficacy and safety of three different doses of the
once-daily human GLP-1 analog liraglutide (0.6 mg, 1.2
mg and 1.8 mg once daily, OD) added to glimepiride (2–
4 mg OD), versus glimepiride alone (placebo) and rosigl-
itazone (4 mg) in combination with glimepiride, in 1041
type 2 diabetic patients. Patients were stratified based on
previous oral antidiabetic drug (OAD) monotherapy or
combination therapy and randomly allocated to any of
the five arms and followed for 26 weeks. The results of the
study showed that all doses of liraglutide plus glimepiride
were associated with an improvement in HbA1c and fast-
ing plasma glucose (FPG) levels compared to placebo,
and that higher doses of liraglutide (1.2 mg and 1.8 mg)
resulted in significantly greater reductions in HbA1c and
greater bodyweight loss compared to rosiglitazone. Rates
of all hypoglycemic events and nocturnal hypoglycemic
events did not significantly differ across treatment arms.
For the purposes of this analysis, we focused only on the
two highest doses of liraglutide (1.2 mg and 1.8 mg) com-
pared to rosiglitazone, all in combination with glimepir-
ide. The 0.6 mg dose of liraglutide was omitted because it
is mainly to be utilized as an escalation dose.
Model
The CORE Diabetes Model (CDM) has been described in
detail previously [31-33]. This interactive computer simu-
lation model has been used to determine the long-term
health outcomes and economic consequences of interven-
tions in type 1 or type 2 diabetes using surrogate clinical
endpoints, such as HbA1c, systolic blood pressure, lipids,
serum cholesterol, and body mass index (BMI) [34-37].
The model has a Markov structure combined with Monte
Carlo simulation and the use of tracker variables, which
allows for the development and progression of multiple
complications in an individual patient over time, improv-
ing the limitations of traditional Markov models. The
CDM predicts the progression of diabetes type 2 over
long-term horizons using the most relevant publishedCardiovascular Diabetology 2009, 8:12 http://www.cardiab.com/content/8/1/12
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epidemiological and clinical data, including studies such
as the United Kingdom Prospective Diabetes Study
(UKPDS) [38]. The CDM includes 15 sub-models to sim-
ulate the most frequent diabetes complications, such as
angina, cataracts, congestive heart failure, foot ulcer and
amputation, hypoglycemia, ketoacidosis, lactic acidosis,
macular edema, myocardial infarction, nephropathy, neu-
ropathy, peripheral vascular disease, retinopathy, stroke,
and non-specific mortality. These sub-models run in par-
allel to allow the hypothetical subjects to develop con-
comitant complications as appropriate. Cohorts can be
defined using demographic characteristics in terms of age,
gender, baseline risk factors and pre-existing complica-
tions. This model has been validated against 66 published
studies, including external (third-order) validation of sim-
ulations of type 2 diabetes [32].
Interventions
Data on the treatment effects of liraglutide 1.2 mg and 1.8
mg or rosiglitazone added to glimepiride were extracted
from the LEAD-1 study (Table 1).
Simulation cohorts
An analytic cohort of 5000 simulated patients was assem-
bled using the treatment-specific baseline demographics
and risk factors from the LEAD-1 study (Table 2)
[18,25,39,40]. The LEAD-1 study was conducted in 21
countries throughout Europe and Asia. Subjects had a
mean duration of diagnosed diabetes of 7.9 years, were
56.1 years old, and had an average BMI of 29.9 kg/m2.
This trial is described greater in detail by Marre et al. [25].
Treatment specific changes in glycemic control, blood
pressure, BMI, and lipids were used to determine the inci-
dence and time to onset of complications, predicted sur-
vival, and cost of complications.
Analysis
A US healthcare payer perspective was used for the cost
analysis. Only direct medical costs of complications are
included in the analysis and a discount rate of 3% annu-
ally was applied to costs beyond year 1. Table 3 displays
the cost inputs used in the simulation [10,41-45]. Drug
costs were not applied for the three treatment groups,
including the cost of glimepiride, as the price of liraglutide
is unknown and applying only the rosiglitazone price
would bias the findings in favor of liraglutide. Three ana-
lytic time horizons (10, 20 and 30 years) were selected for
simulation. Longer-term horizons permit a more com-
plete estimation of complication rates and predicted sur-
vival. For sensitivity analysis, the lower and upper limits
of the 95% confidence intervals (CI) reported for the
changes in HbA1c for each of the three treatment groups
were used.
Results
Table 4 reports the predicted survival, cardiovascular mor-
tality, event rates for complications and costs. These
results are reported for the three treatment groups in
LEAD-1 and for the three analytic time horizons.
As expected, predicted overall survival declined and com-
plication rates increased for all three treatments as the
analytic horizon was extended from 10 to 30 years. Over-
all survival in both liraglutide-treated groups was higher
than in the rosiglitazone-treated group at all three time
points. After 30 years the differences in survival were 2.4%
and 3.6% higher in the group treated with liraglutide 1.2
mg and 1.8 mg respectively, compared to rosiglitazone.
Complication rates were higher at all three time points for
the rosiglitazone group compared to the two liraglutide
groups.
Applying the unit cost data in Table 3 to the event rate pre-
dictions from Table 4 produced an estimate of total costs
of complications during the follow-up up to 30 years
excluding the costs of liraglutide and rosiglitazone as the
cost for the former is presently unknown since the medi-
cation is not presently FDA approved or marketed. Total
Table 1: Treatment-specific changes from baseline from LEAD-1 Study
Liraglutide 1.8 mg Liraglutide 1.2 mg Rosiglitazone 4 mg
Mean change SD Mean change SD Mean change SD
HbA1c (%) -1.13* 1.05 -1.08* 1.04 -0.44 1.05
SBP (mmHg) -2.81 13.07 -2.56 12.72 -0.93 12.71
Total cholesterol (mg/dl) -11.99* 37.97 5.06 37.31 7.42 37.14
LDL (mg/dl) -8.09* 29.85 -2.36 29.28 4.43 29.15
HDL (mg/dl) -1.57* 7.50 -0.84 7.28 0.75 7.23
Triglycerides (mg/dl) -14.72* 132.28 -17.64* 130.23 1.73 129.63
BMI -0.08* 1.11 0.12 1.13 0.78 1.13
Major hypoglycemic event/year 0.01 0 0
Minor hypoglycemic event/year 0.47 0.50 0.12
*Statistically significant (p < 0.05) compared to rosiglitazone 4 mg.
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.Cardiovascular Diabetology 2009, 8:12 http://www.cardiab.com/content/8/1/12
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cumulative costs per patient, defined as the management
costs, costs of ongoing disease complications and costs of
acute events related to the disease, during the 30 years of
follow-up were $276 dollars lower in the group treated
with liraglutide 1.2 mg compared to liraglutide 1.8 mg,
and $1438 dollars lower compared to the rosiglitazone
group (Table 4). As expected, the costs related to cardio-
vascular events were the main factor in all groups, repre-
senting 57.4% of the total costs per patient for liraglutide
1.2 mg, 58.5% for liraglutide 1.8 mg, and 59.1% for ros-
iglitazone. Management costs and costs related to the
treatment of ulcers, amputations and neuropathies were
lower in the rosiglitazone group (Figure 1).
We used the upper and lower limits of the 95% CI of the
reported changes in HbA1c for each of the three treatment
Table 2: Cohort characteristics at baseline
Characteristic Baseline value SD Reference
Demographics
Mean age (years) 56.1 9.8 25
Duration of diabetes (years) 7.9 5.4 25
Proportion male (%) 49.4 25
Risk factors
HbA1c (%) 8.4 0.9 25
SBP (mmHg) 132.1 15.4 25
BMI (kg/m2) 29.9 5.1 25
Total cholesterol (mg/dl) 196.15 42.3 25
LDL (mg/dl) 130.76 38.46 25
HDL (mg/dl) 50 11.53 25
Triglycerides (mg/dl) 190.9 145.5 25
Ethnic group (%)
White 64.5 Novo Nordisk, data on file
Black 2.9 Novo Nordisk, data on file
Asian 32.5 Novo Nordisk, data on file
Cardiovascular disease
Stroke (%) 0.9 Novo Nordisk, data on file
Angina pectoris (%) 1.0 Novo Nordisk, data on file
MI (%) 1.4 Novo Nordisk, data on file
CHF (%) 0.1 Novo Nordisk, data on file
Atrial fibrillation (%) 1.5 Novo Nordisk, data on file
LVH by ECG (%) 0.7 Novo Nordisk, data on file
PVD (%) 0.8 Novo Nordisk, data on file
Renal disease
Microalbuminuria (%) 1.1 Novo Nordisk, data on file
Gross proteinuria (%) 0.1 Novo Nordisk, data on file
End-stage renal disease (%) 0.1 Novo Nordisk, data on file
Retinopathy
Background diabetic retinopathy (%) 14.9 Novo Nordisk, data on file
Proliferative diabetic retinopathy (%) 0.1 Novo Nordisk, data on file
Other complications
Peripheral neuropathy (%) 20.0 Novo Nordisk, data on file
Foot ulcer (%) 0.1 Novo Nordisk, data on file
Amputation (%) 0.3 Novo Nordisk, data on file
Cataract (%) 5.6 Novo Nordisk, data on file
Macular edema (%) 0.2 Novo Nordisk, data on file
Severe vision loss (%) 0.1 Novo Nordisk, data on file
Patient management
ACE-I/ARBs (%) 48.7 18
Statins (%) 28.2 18
Aspirin (%) 43.9 18
Screened for retinopathy (%) 67.7 39
Screened for renal disease (%) 55 40
Screened for foot disease (%) 68.3 39
ARB, angiotensin receptor blocker; ACE-I angiotensin-converting enzyme inhibitor; BMI, body mass index; CHF, congestive heart failure; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; LVH by ECG, left ventricular hypertrophy confirmed by electrocardiogram; MI, myocardial 
infarction; PVD, peripheral vascular disease; SBP, systolic blood pressure.Cardiovascular Diabetology 2009, 8:12 http://www.cardiab.com/content/8/1/12
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Table 3: Cost inputs: US perspective
Values Units Reference
Discount rates
Discount clinical 0.00 41
Discount costs 0.03 41
Management costs
Annual statins 947.74 US$ 42
Annual cost aspirin 23.01 US$ 42
Annual cost ACE 426.21 US$ 42
Annual cost screening for microalbuminuria 18.62 US$ 10
Annual cost screening for GFR 27.4 US$ 10
Stopping ACEs due to adverse events 0 US$ NA
Annual cost of eye screening 82.18 US$ 10
Foot screening program (monthly based) 0 US$ NA
Non-standard ulcer treatment (e.g. topical becaplermin) (monthly based) 167.64 US$ 43
Costs for CVD complications
MI year 1 37,421 US$ 10
MI year 2 and onwards 2,069 US$ 10
Angina year 1 7,424 US$ 10
Angina year 2 and onwards 1,917 US$ 10
CHF year 1 3,214 US$ 10
CHF year 2 and onwards 3,214 US$ 10
Stroke year 1 49,556 US$ 10
Stroke year 2 and onwards 16,539 US$ 10
Stroke death within 30 days 0U S $ N A
PVD year 1 4,707 US$ 44
PVD year 2 and onwards 4,707 US$ 44
Costs: renal complications
Hemodialysis costs year 1 45,638 US$ 10
Annual costs HD year 2 and onwards 45,638 US$ 10
Peritoneal dialysis costs year 1 45,638 US$ 10
Annual costs PD year 2 and onwards 45,638 US$ 10
Renal transplant costs year 1 45,638 US$ 10
Annual costs year 2 and onwards 0 US$ NA
Costs: acute events
Major hypoglycemic event 1,191 US$ 10
Ketoacidosis event 13,404 US$ 10
Lactic acid event 0U S $ N A
Costs: eye disease
Laser treatment 834 US$ 10
Cataract operation 2,655 US$ 10
Annual costs following cataract operation 0 US$ 44
Blindness year 1 4,039 US$ 10
Blindness year 2 and onwards 4,039 US$ 10
Costs neuropathy/foot ulcer/amputation
Neuropathy year 1 408 US$ 10
Neuropathy year 2 and onwards 408 US$ 10
Amputation (event-based) 33,257 US$ 10
Amputation prosthesis (event based) 1,195 US$ 10
Gangrene treatment (monthly based) 6,240 US$ 45
After healed ulcer (yearly based) 0 US$ NA
Infected ulcer (monthly based) 3,198 US$ 45
Standard uninfected ulcer (monthly based) 1,769 US$ 45
Healed ulcer history of amputation (yearly based) 0 US$ NA
ACE, angiotensin-converting enzyme; CHF, congestive heart failure; CVD, cardiovascular disease; GFR, glomerular filtration rate; MI, myocardial 
infarction; PVD, peripheral vascular disease.Cardiovascular Diabetology 2009, 8:12 http://www.cardiab.com/content/8/1/12
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Table 4: Predicted survival, events and costs by treatment group and time horizon
Treatment 
group
Time 
horizon 
(years)
Survival 
rates (%)
Number of events in a hypothetical population of 5000 subjects Average cumulative 
costs of 
complications per 
patient 
(US$- discounted)
CVD MI Stroke CHF Renal 
disorders 
(including 
ESRD death)*
Visual 
disorders
†
Amputation 
(first and 
recurrent)
N (%)
Liraglutide 
1.2 mg
10 82.4 727 14.54% 346 140 381 621 1261 144 14,126.53
20 49.0 2,049 40.98% 900 381 992 1322 2534 384 29,850.63
30 15.0 3,484 69.68% 1373 563 1476 1756 3242 565 38,963.07
Liraglutide 
1.8 mg
10 82.3 728 14.56% 355 160 391 622 1271 115 14,162.06
20 49.2 2,017 40.34% 881 421 987 1296 2578 358 30,021.86
30 16.0 3,419 68.38% 1323 611 1478 1695 3233 529 39,239.92
Rosiglitazo
ne 4 mg
10 80.8 782 15.64% 444 161 422 804 1548 113 15,237.10
20 45.5 2,227 44.54% 1062 385 1060 1541 2910 347 31,243.92
30 12.6 3,624 72.48% 1574 586 1489 1923 3529 507 40,401.96
*Microalbuminuria + Gross proteinuria + ESRD + ESRD death.
†Background retinopathy + proliferative retinopathy + macular edema + severe vision loss + Cataract.
CHF, congestive heart failure; CVD, cardiovascular death; ESRD, end-stage renal disease MI, myocardial infarction.
Breakdown of medical costs Figure 1
Breakdown of medical costs. CVD, cardiovascular disease.
Total costs Management CVD Renal Ulcer/Amp/Neuro Eye
45,000
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27,000
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9,000
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Liraglutide 1.2 mg
Liraglutide 1.8 mg
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groups to evaluate the sensitivity of our findings to uncer-
tainty in the treatment benefit. The absolute survival and
event rates changed slightly across all three time periods:
less than 5% in either direction depending on whether the
simulations were run using the upper or lower bound of
the CI. In neither case did the model produce predicted
outcomes for the rosiglitazone group that were better than
either liraglutide group.
Discussion
As there are no long-term follow-up studies of liraglutide
or rosiglitazone measuring mortality as the primary end-
point, reliance must be placed on simulation models that
have reproduced accurately the outcomes of long-term
cohorts of patients with diabetes [46]. Our modelling
study has shown that, in patients with type 2 diabetes
treated with glimepiride, adding liraglutide 1.8 mg or 1.2
mg, compared to adding rosiglitazone 4 mg, may lead to
improved survival and reductions in complications over a
10 to 30-year period. Additionally, the groups treated with
liraglutide had a higher projected survival rate and lower
cumulative medical costs, compared to rosiglitazone.
These differences increase over time but are noticeable
even after the first 10 years of follow-up. The lower
number of complications related to ulcers and amputa-
tions in the rosiglitazone treatment group, compared to
the two groups with liraglutide, may be explained in part
by the lower survival time, as there is less chance of this
type of complication with the shorter exposure time.
Other events, such as visual disorders, are influenced by
additional factors, especially changes in blood pressure,
hence the effects of the therapies on blood pressure
should be considered and could support an explanation
of these differences; in the LEAD-1 study, liraglutide 1.8
mg and 1.2 mg showed a higher reduction of systolic
blood pressure compared to rosiglitazone (-2.81 mmHg, -
2.56 mmHg, and -0.93 mmHg, respectively).
As expected, cardiovascular events were the leading cause
of death across all groups; nevertheless the survival rate
was relatively higher than that usually expected in these
patients. This may be caused by a study effect, as the pop-
ulation from the LEAD-1 study, used for this simulation
study, could be considered 'healthier' than the average
type 2 diabetic patient after 8 years of diagnosis. Most
patients were recruited in European and Asian countries,
with mean near normal levels of total cholesterol, low-
density lipoprotein, high-density lipoprotein, and triglyc-
erides. Further, a very low proportion of patients reported
a previous cardiovascular event or renal impairment at
baseline.
Cardiovascular disease was also the main contributor to
the cumulative costs for all groups, and explains in great
part the overall higher costs of the rosiglitazone group,
despite the lower survival time of this group, and lower
costs in management and complications related to neu-
ropathy, ulcers, and amputations. The safety of liraglutide
and rosiglitazone, specifically regarding minor and major
hypoglycemic events, was also projected from the LEAD-1
study, probably underestimating the real effect in events
and costs for a longer follow-up. Treatment switching,
dose adjustments and adherence were not considered to
have any effect in the simulation, thus providing an ideal
scenario that may be more optimistic than actual practice,
but the effect could be non-differential across treatments
and therefore keep the trend in differences as reported
here, probably with a higher number of events earlier in
the follow-up.
We would like to point out a few additional limitations of
the research. Although the model uses data from epidemi-
ologic and clinical trials, some recently published studies
have called into question the cardiovascular benefits of
intensive glycemic control in patients with longer dura-
tion of diabetes and/or existing diabetes complications
[18,22]. It is important to note that, at the time of writing,
these newer data have not yet been incorporated into the
CORE diabetes model, so the potentially negative effect of
more intensive treatments is not considered; only infor-
mation from the ADVANCE trial was used as the reference
for the current management of diabetic patients in the use
of aspirin, statins, and angiotensin receptor blocker
(ARB)/angiotensin-converting enzyme (ACE) inhibitors.
The effect of rosiglitzaone on systolic blood pressure in
LEAD-1 may be underestimated when compared to evi-
dence from other trials [47]. One important caution when
interpreting the results of the cumulative costs is that the
costs of adding liraglutide or rosiglitazone to glimepiride
treatment are not included because liraglutide is not on
the market and the price is not known. More specific
research will be required to determine the cost-effective-
ness of the treatments.
In the sensitivity analysis, only changes in HbA1c were
considered, using the lower and upper limits of the 95%
CI for every treatment as this was the primary endpoint of
the LEAD-1 study. Nevertheless, other significant changes
in the study, that is, blood pressure, lipids and weight,
could have been included, thereby increasing the uncer-
tainty of estimates in the simulation but assessing a more
comprehensive effect of these therapies.
Finally, the utility of diabetes models to predict life
expectancy and other disease outcomes with precision is
open to criticism. Models are imperfect instruments of
real world outcomes. Nevertheless, attempts to correlate
diabetes model predictions of outcomes with the results
of long-term trials have been undertaken. These studiesCardiovascular Diabetology 2009, 8:12 http://www.cardiab.com/content/8/1/12
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have shown that models can produce findings broadly
consistent with long-trials under specified conditions
[48].
Conclusion
This study represents one of the first uses of a disease sim-
ulation model to examine the long-term clinical effects of
a GLP-1 by incorporating data from a head-to-head active
comparator clinical trial. This study represents an impor-
tant advance relative to previously published works,
which were based on modelling data from placebo-con-
trolled clinical trials [39]. Notably, the availability of
head-to-head clinical trial data and the incorporation of
active-comparator designs as part of the registration study
program provide valuable additional therapeutic infor-
mation for healthcare decision-makers during the imme-
diate post-launch experience.
This study shows that in patients with type 2 diabetes
treated with glimepiride, adding liraglutide 1.8 mg or 1.2
mg, compared to adding rosiglitazone 4 mg, may improve
survival rates and reductions in complications over a 10-
to 30-year period. The liraglutide 1.2 mg and 1.8 mg
groups had higher projected survival rates and lower
cumulative costs, compared to rosiglitazone 4 mg.
Improvements in the cardiovascular event rates are impor-
tant as these events are the main contributor to death and
increased cost of treating type 2 diabetes.
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